Clinical trial diversity is not optional—it’s critical. As Dr. Gail Kerr, AWIR’s Director of Clinical Research, emphasizes: “Diversity in clinical trials is essential to understanding how various treatment approaches work in patients from different gene pools, backgrounds, and environments. When research subjects don’t reflect the populations a treatment is designed for, it undermines the quality of care for both patients and physicians, and threatens our ability to practice high-quality medicine.” The ripple effects of this extend beyond underrepresentation into: 1️⃣ Limited understanding of disease subtype and variations. 2️⃣ Inappropriate treatment and management strategies. 3️⃣ Suboptimal care for vulnerable populations. 4️⃣ Increasing disparities and mistrust among underserved communities. AWIR is committed to advancing equity through research that addresses these gaps and improves outcomes for all patients. Learn how we’re tackling these challenges: bit.ly/4gEX2eE #DiversityInResearch #ClinicalTrialsMatter #HealthEquity #AWIRLeadership